{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:45:11Z","timestamp":1793598311607,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"44","license":[{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1038\/onc.2017.209","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T11:07:38Z","timestamp":1499684858000},"page":"6143-6153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":348,"title":["Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers"],"prefix":"10.1038","volume":"36","author":[{"given":"Y","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"key":"BFonc2017209_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"BFonc2017209_CR2","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1136\/gutjnl-2014-307323","volume":"63","author":"G Giannelli","year":"2014","unstructured":"Giannelli G, Rani B, Dituri F, Cao Y, Palasciano G . Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut 2014; 63: 1668\u20131676.","journal-title":"Gut"},{"key":"BFonc2017209_CR3","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1200\/JCO.2010.27.9992","volume":"28","author":"C Ferrone","year":"2010","unstructured":"Ferrone C, Dranoff G . Dual roles for immunity in gastrointestinal cancers. J Clin Oncol 2010; 28: 4045\u20134051.","journal-title":"J Clin Oncol"},{"key":"BFonc2017209_CR4","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1038\/onc.2016.34","volume":"35","author":"EW Lin","year":"2016","unstructured":"Lin EW, Karakasheva TA, Hicks PD, Bass AJ, Rustgi AK . The tumor microenvironment in esophageal cancer. Oncogene 2016; 35: 5337\u20135349.","journal-title":"Oncogene"},{"key":"BFonc2017209_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2174\/1574888X09666140812112305","volume":"10","author":"L Zhang","year":"2015","unstructured":"Zhang L, Song X, Mohri Y, Qiao L . Role of inflammation and tumor microenvironment in the development of gastrointestinal cancers: what induced pluripotent stem cells can do? Curr Stem Cell Res Ther 2015; 10: 245\u2013250.","journal-title":"Curr Stem Cell Res Ther"},{"key":"BFonc2017209_CR6","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/hep.25777","volume":"56","author":"H Li","year":"2012","unstructured":"Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X et al. Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012; 56: 1342\u20131351.","journal-title":"Hepatology"},{"key":"BFonc2017209_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/hep.26192","volume":"57","author":"Y Wu","year":"2013","unstructured":"Wu Y, Kuang DM, Pan WD, Wan YL, Lao XM, Wang D et al. Monocyte\/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48\/2B4 interactions. Hepatology 2013; 57: 1107\u20131116.","journal-title":"Hepatology"},{"key":"BFonc2017209_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/j.1442-2050.2010.01073.x","volume":"23","author":"M Watanabe","year":"2010","unstructured":"Watanabe M, Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Maruyama T et al. NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma. Dis Esophagus 2010; 23: 675\u2013681.","journal-title":"Dis Esophagus"},{"key":"BFonc2017209_CR9","first-page":"384726","volume":"2011","author":"G Zhang","year":"2011","unstructured":"Zhang G, Liu WL, Zhang L, Wang JY, Kuang MH, Liu P et al. Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma. Clin Dev Immunol 2011; 2011: 384726.","journal-title":"Clin Dev Immunol"},{"key":"BFonc2017209_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.coi.2016.05.006","volume":"41","author":"JA Wargo","year":"2016","unstructured":"Wargo JA, Reddy SM, Reuben A, Sharma P . Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 2016; 41: 23\u201331.","journal-title":"Curr Opin Immunol"},{"key":"BFonc2017209_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP . The future of immune checkpoint therapy. Science 2015; 348: 56\u201361.","journal-title":"Science"},{"key":"BFonc2017209_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.coi.2013.03.003","volume":"25","author":"AO Kamphorst","year":"2013","unstructured":"Kamphorst AO, Ahmed R . Manipulating the PD-1 pathway to improve immunity. Curr Opin Immunol 2013; 25: 381\u2013388.","journal-title":"Curr Opin Immunol"},{"key":"BFonc2017209_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-016-0539-x","volume":"15","author":"Y Li","year":"2016","unstructured":"Li Y, Liang L, Dai W, Cai G, Xu Y, Li X et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer 2016; 15: 55.","journal-title":"Mol Cancer"},{"key":"BFonc2017209_CR14","doi-asserted-by":"crossref","first-page":"30772","DOI":"10.18632\/oncotarget.8956","volume":"7","author":"K Chen","year":"2016","unstructured":"Chen K, Cheng G, Zhang F, Zhang N, Li D, Jin J et al. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget 2016; 7: 30772\u201330780.","journal-title":"Oncotarget"},{"key":"BFonc2017209_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/jso.23281","volume":"107","author":"H Saito","year":"2013","unstructured":"Saito H, Kuroda H, Matsunaga T, Osaki T, Ikeguchi M . Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J Surg Oncol 2013; 107: 517\u2013522.","journal-title":"J Surg Oncol"},{"key":"BFonc2017209_CR16","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1097\/PAS.0000000000000698","volume":"40","author":"C Ma","year":"2016","unstructured":"Ma C, Patel K, Singhi AD, Ren B, Zhu B, Shaikh F et al. Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein\u2013Barr virus or microsatellite instability. Am J Surg Pathol 2016; 40: 1496\u20131506.","journal-title":"Am J Surg Pathol"},{"key":"BFonc2017209_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.clcc.2016.07.007","volume":"15","author":"JW Toh","year":"2016","unstructured":"Toh JW, de Souza P, Lim SH, Singh P, Chua W, Ng W et al. The potential value of immunotherapy in colorectal cancers: review of the evidence for programmed death-1 inhibitor therapy. Clin Colorectal Cancer 2016; 15: 285\u2013291.","journal-title":"Clin Colorectal Cancer"},{"key":"BFonc2017209_CR18","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.3748\/wjg.v22.i28.6469","volume":"22","author":"E Moreno-Cubero","year":"2016","unstructured":"Moreno-Cubero E, Larrubia JR . Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World J Gastroenterol 2016; 22: 6469\u20136483.","journal-title":"World J Gastroenterol"},{"key":"BFonc2017209_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252\u2013264.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2017209_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S . Functions of natural killer cells. Nat Immunol 2008; 9: 503\u2013510.","journal-title":"Nat Immunol"},{"key":"BFonc2017209_CR21","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","volume":"17","author":"C Guillerey","year":"2016","unstructured":"Guillerey C, Huntington ND, Smyth MJ . Targeting natural killer cells in cancer immunotherapy. Nat Immunol 2016; 17: 1025\u20131036.","journal-title":"Nat Immunol"},{"key":"BFonc2017209_CR22","doi-asserted-by":"publisher","first-page":"e1178421","DOI":"10.1080\/2162402X.2016.1178421","volume":"5","author":"V Bucklein","year":"2016","unstructured":"Bucklein V, Adunka T, Mendler AN, Issels R, Subklewe M, Schmollinger JC et al. Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients. Oncoimmunology 2016; 5: e1178421.","journal-title":"Oncoimmunology"},{"key":"BFonc2017209_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00262-016-1882-x","volume":"66","author":"R Tarazona","year":"2016","unstructured":"Tarazona R, Sanchez-Correa B, Casas-Aviles I, Campos C, Pera A, Morgado S et al. Immunosenescence: limitations of natural killer cell-based cancer immunotherapy. Cancer Immunol Immunother 2016; 66: 233\u2013245.","journal-title":"Cancer Immunol Immunother"},{"key":"BFonc2017209_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/cmi.2015.81","volume":"14","author":"Y Chen","year":"2017","unstructured":"Chen Y, Chen B, Yang T, Xiao W, Qian L, Ding Y et al. Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells. Cell Mol Immunol 2017; 14: 293\u2013307.","journal-title":"Cell Mol Immunol"},{"key":"BFonc2017209_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1189\/jlb.4A0115-003RR","volume":"99","author":"S Solaymani-Mohammadi","year":"2016","unstructured":"Solaymani-Mohammadi S, Lakhdari O, Minev I, Shenouda S, Frey BF, Billeskov R et al. Lack of the programmed death-1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules. J Leukoc Biol 2016; 99: 475\u2013482.","journal-title":"J Leukoc Biol"},{"key":"BFonc2017209_CR26","doi-asserted-by":"publisher","first-page":"e0137646","DOI":"10.1371\/journal.pone.0137646","volume":"10","author":"SS Hassan","year":"2015","unstructured":"Hassan SS, Akram M, King EC, Dockrell HM, Cliff JM . PD-1, PD-L1 and PD-L2 gene expression on T-cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment. PLoS One 2015; 10: e0137646.","journal-title":"PLoS One"},{"key":"BFonc2017209_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1089\/vim.2011.0096","volume":"25","author":"S Norris","year":"2012","unstructured":"Norris S, Coleman A, Kuri-Cervantes L, Bower M, Nelson M, Goodier MR . PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection. Viral Immunol 2012; 25: 329\u2013332.","journal-title":"Viral Immunol"},{"key":"BFonc2017209_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/eji.201141832","volume":"42","author":"S Wiesmayr","year":"2012","unstructured":"Wiesmayr S, Webber SA, Macedo C, Popescu I, Smith L, Luce J et al. Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD. Eur J Immunol 2012; 42: 541\u2013550.","journal-title":"Eur J Immunol"},{"key":"BFonc2017209_CR29","doi-asserted-by":"publisher","first-page":"e1001347","DOI":"10.1371\/journal.ppat.1001347","volume":"7","author":"Y Chen","year":"2011","unstructured":"Chen Y, Wu S, Guo G, Fei L, Guo S, Yang C et al. Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection. PLoS Pathog 2011; 7: e1001347.","journal-title":"PLoS Pathog"},{"key":"BFonc2017209_CR30","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.4049\/jimmunol.180.6.3637","volume":"180","author":"L Golden-Mason","year":"2008","unstructured":"Golden-Mason L, Klarquist J, Wahed AS, Rosen HR . Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol 2008; 180: 3637\u20133641.","journal-title":"J Immunol"},{"key":"BFonc2017209_CR31","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","volume":"116","author":"DM Benson Jr.","year":"2010","unstructured":"Benson DM Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B et al. The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116: 2286\u20132294.","journal-title":"Blood"},{"key":"BFonc2017209_CR32","doi-asserted-by":"publisher","first-page":"e0134715","DOI":"10.1371\/journal.pone.0134715","volume":"10","author":"BY Huang","year":"2015","unstructured":"Huang BY, Zhan YP, Zong WJ, Yu CJ, Li JF, Qu YM et al. The PD-1\/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells. PLoS One 2015; 10: e0134715.","journal-title":"PLoS One"},{"key":"BFonc2017209_CR33","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","volume":"139","author":"S Pesce","year":"2017","unstructured":"Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol 2017; 139: 335\u2013346.e3.","journal-title":"J Allergy Clin Immunol"},{"key":"BFonc2017209_CR34","doi-asserted-by":"publisher","first-page":"72961","DOI":"10.18632\/oncotarget.12150","volume":"7","author":"A Beldi-Ferchiou","year":"2016","unstructured":"Beldi-Ferchiou A, Lambert M, Dogniaux S, Vely F, Vivier E, Olive D et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget 2016; 7: 72961\u201372977.","journal-title":"Oncotarget"},{"key":"BFonc2017209_CR35","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1172\/JCI66381","volume":"123","author":"H Peng","year":"2013","unstructured":"Peng H, Jiang X, Chen Y, Sojka DK, Wei H, Gao X et al. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J Clin Invest 2013; 123: 1444\u20131456.","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"BFonc2017209_CR36","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/S0140-6736(15)60360-9","volume":"385","author":"T Hydes","year":"2015","unstructured":"Hydes T, Abuhilal M, Armstrong T, Primrose J, Takhar A, Khakoo S . Natural killer cell maturation markers in the human liver and expansion of an NKG2C+KIR+ population. Lancet 2015; 385 (Suppl 1): S45.","journal-title":"Lancet"},{"key":"BFonc2017209_CR37","doi-asserted-by":"publisher","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","volume":"181","author":"AL Kinter","year":"2008","unstructured":"Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA et al. The common \u03b3-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008; 181: 6738\u20136746.","journal-title":"J Immunol"},{"key":"BFonc2017209_CR38","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1084\/jem.20061496","volume":"203","author":"C Petrovas","year":"2006","unstructured":"Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203: 2281\u20132292.","journal-title":"J Exp Med"},{"key":"BFonc2017209_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","volume":"229","author":"JL Riley","year":"2009","unstructured":"Riley JL . PD-1 signaling in primary T cells. Immunol Rev 2009; 229: 114\u2013125.","journal-title":"Immunol Rev"},{"key":"BFonc2017209_CR40","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25: 9543\u20139553.","journal-title":"Mol Cell Biol"},{"key":"BFonc2017209_CR41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3389\/fimmu.2015.00355","volume":"6","author":"AK Ali","year":"2015","unstructured":"Ali AK, Nandagopal N, Lee SH . IL-15-PI3K-AKT-mTOR: a critical pathway in the life journey of natural killer cells. Front Immunol 2015; 6: 355.","journal-title":"Front Immunol"},{"key":"BFonc2017209_CR42","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/1078-0432.CCR-15-1352","volume":"22","author":"L Shi","year":"2016","unstructured":"Shi L, Chen L, Wu C, Zhu Y, Xu B, Zheng X et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin Cancer Res 2016; 22: 1173\u20131184.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017209_CR43","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568\u2013571.","journal-title":"Nature"},{"key":"BFonc2017209_CR44","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366: 2455\u20132465.","journal-title":"N Engl J Med."},{"key":"BFonc2017209_CR45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","volume":"54","author":"C Blank","year":"2005","unstructured":"Blank C, Gajewski TF, Mackensen A . Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005; 54: 307\u2013314.","journal-title":"Cancer Immunol Immunother"},{"key":"BFonc2017209_CR46","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pharmthera.2013.12.004","volume":"142","author":"J Polivka Jr.","year":"2014","unstructured":"Polivka J Jr., Janku F . Molecular targets for cancer therapy in the PI3K\/AKT\/mTOR pathway. Pharmacol Ther 2014; 142: 164\u2013175.","journal-title":"Pharmacol Ther"},{"key":"BFonc2017209_CR47","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1136\/gutjnl-2014-307671","volume":"64","author":"W Yan","year":"2015","unstructured":"Yan W, Liu X, Ma H, Zhang H, Song X, Gao L et al. Tim-3 fosters HCC development by enhancing TGF-beta-mediated alternative activation of macrophages. Gut 2015; 64: 1593\u20131604.","journal-title":"Gut"},{"key":"BFonc2017209_CR48","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/ni.3470","volume":"17","author":"RB Delconte","year":"2016","unstructured":"Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat Immunol 2016; 17: 816\u2013824.","journal-title":"Nat Immunol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2017209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2017209","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/onc.2017.209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/onc2017209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T01:01:22Z","timestamp":1684458082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2017209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":48,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["BFonc2017209"],"URL":"https:\/\/doi.org\/10.1038\/onc.2017.209","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]},"assertion":[{"value":"12 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}